Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2003

View Archived Issues

Manufacturing process established for ProSavin

CAB-175 enters phase I testing

Hedgehog compounds to be studied for the treatment of ALS

Biosyn submits IND for HIV microbicide UC-781

Introgen and NCI enter CTA for development of Advexin

Preclinical studies support use of MT-103 for chronic lymphocytic leukemia

Wilex radioimmunotherapy enters clinical evaluation in biliary cancers

Nuvelo initiates phase II testing with alfimeprase in acute peripheral arterial occlusion

Aventis develops new tubulin polymerization inhibitors

Dr. Reddy's presents new PPARalpha agonists in recent patent

Tularik and Roche describe novel IKK inhibitors and their use

AstraZeneca claims new IGF-1R modulators with utility in cancer therapy

Calyx patent covers new agents for diabetes, inflammation, etc.

New antibacterial oxazolidinones designed by Merck and Kyorin team

New urokinase inhibitors under study at Corvas

U.K. approval for Testim

Promising phase II findings for Alzhemed in Alzheimer's disease

Serostim not recommended for short bowel syndrome

Onyx prioritizes Bay-43-9006 program, discontinues therapeutic virus program

Aventis and Zealand sign licensing agreement for ZP-10

ETC-216 produces regression of atherosclerosis

European phase III phenserine trial gets under way

Four new trials expand evaluation of Genasense

FDA approves Pravigard PAC

Anidulafungin NDA accepted for review

Selective human histamine H4 receptor ligand discovered by international team

Orally active KCNQ2 channel opener with potential in the treatment of migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...